Índice
Literatura académica sobre el tema "Déprivation androgénique"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Déprivation androgénique".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Déprivation androgénique"
Dariane, Charles, Manon Baures, Julien Anract, Nicolas Barry Delongchamps, Jacques-Emmanuel Guidotti y Vincent Goffin. "Progéniteurs luminaux prostatiques". médecine/sciences 39, n.º 5 (mayo de 2023): 429–36. http://dx.doi.org/10.1051/medsci/2023058.
Texto completoFrambati, Laura, Kerstin Weber, Alessandra Canuto, João Flores Alves Dos Santos, Raymond Miralbell, Thomas Zilli, Nadine Voison, Claude Pichard y Caroline Joly. "Cancer de la prostate et déprivation androgénique : bénéfices d’un accompagnement psychologique". Revue Médicale Suisse 9, n.º 373 (2013): 369–73. http://dx.doi.org/10.53738/revmed.2013.9.373.0369.
Texto completoMareschal, J., L. Frambati, E. Biason, S. Philipp-Paradisi, P. Rigoli, K. Weber, T. Zilli, R. Miralbell y C. Pichard. "P256: Cancer de la prostate et déprivation androgénique chez des patients fragiles : « ADAPP » un programme de soins multidisciplinaire prospectif de 2 ans. Données préliminaires". Nutrition Clinique et Métabolisme 28 (diciembre de 2014): S203. http://dx.doi.org/10.1016/s0985-0562(14)70898-2.
Texto completoManolache, Narcis-Georges, Georges Mjaess, Romain Diamand, Simone Albisinni y Thierry Roumeguère. "Cancer de Prostate, Déprivation Androgénique, et Risques d’Infection par la COVID-19 : Revue Systématique et Méta-Analyse". Progrès en Urologie, septiembre de 2022. http://dx.doi.org/10.1016/j.purol.2022.09.005.
Texto completoTesis sobre el tema "Déprivation androgénique"
Boue, Antoine. "Ιmpact cοgnitif des hοrmοnοthérapies du cancer de la prοstate : changements cοgnitifs οbjectifs et subjectifs cοnsécutifs à la déprivatiοn andrοgénique seule οu assοciée à une hοrmοnοthérapie de nοuvelle génératiοn". Electronic Thesis or Diss., Normandie, 2024. http://www.theses.fr/2024NORMC414.
Texto completoAndrogen deprivation is a standard-of-care option for advanced prostate cancer. New androgen receptor pathway inhibitors have been developed for patients with castration resistance. Among them, enzalutamide and abiraterone acetate are used for the treatment of metastatic prostate cancer in combination with androgen deprivation therapy. Androgen deprivation alone is known to impact cognition. Elderly patients, who represent the majority of prostate cancer patients, are at higher risk of cognitive impairment. In these patients, cognitive impairment can affect their autonomy and the course of care.This thesis aimed to evaluate the cognitive impact of hormone therapy for prostate cancer. A meta-analysis was conducted to identify the cognitive domains most affected by these treatments. It revealed a decline in subjective cognition (self-perceived cognition assessed with questionnaire) during androgen deprivation therapy alone or in combination with next-generation hormone therapy. In addition, a study was conducted with patients aged 70 and older, treated with enzalutamide or abiraterone acetate for metastatic castration-resistant prostate cancer. Before treatment, these patients exhibited frequent cognitive impairment. The addition of enzalutamide or abiraterone acetate to androgen deprivation therapy impacted both objective (processing speed and attention, assessed with cognitive tests) and subjective cognition
Aarab-Terrisse, Safae. "Impact de l'axe microbiome-thymus sur l'efficacité de la déprivation androgénique et sur le renforcement de l’immuno-surveillance dans le cancer de la prostate Immunodynamics of Explanted Human Tumors for Precision and Personalized Immuno-Oncology Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients". Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASL025.
Texto completoAndrogen deprivation therapy (ADT) is the backbone treatment for Prostate cancer (PCa), but most patients will become refractory to castration (CRPC). In addition, immune checkpoint blockade may not be an option for CRPC. Given that advanced cancer patients may exhibit a gut dysbiosis and the pivotal role of the intestinal microbiota composition in dictating the success of chemo-and immuno-therapy, we analyzed the role of the immune system, the impact of the gut microbiota and the inter-relationship between both components in the time to CRPC in PCa patients and in a mouse model of prostate cancer (MyC-CaP cell line). First, using CD4 or CD8 depleting antibodies and athymic nude mice, we demonstrated the key role of T lymphocytes in the time to progression during ADT. Secondly, using cohousing experiments, fecal microbial transplantation and broad spectrum antibiotics, we unveiled the seminal role of the host microbiota in governing tumor growth control during ADT. Third, metagenomics coupled with metabolomics analyses highlighted significant changes associated with ADT, their physiological relevance being currently investigated. Finally, while the development of PCa compromises the thymus integrity despite ADT; healthy microbiota restores thymopoiesis and the emigration of mature lymphocytes associated with effective anticancer immunosurveillance. Altogether, ADT mediates a full blown T cell-dependent anti-PCa cancer efficacy when intestinal dysbiosis is compensated by FMT or immunogenic probiotics